Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BioSyent Inc. (V:RX)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 170 Attwell Dr Suite 520
Tel: 1-905-2060013
IR: See website
Key People
Rene C. Goehrum
Chairman of the Board, President, Chief Executive Officer
Robert Joseph March
Chief Financial Officer, Senior Vice President - Finance
Kevin Wilson
Vice President - Sales and Marketing of BioSyent Pharma Inc
Business Overview
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
Financial Overview
For the three months ended 31 March 2020, Biosyent Inc. revenues increased 35% to C$6.1M. Net income increased 48% to C$1.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Employee cost decrease of 4% to C$621K (expense), Net Foreign Exchange (Gains) Losses increase of 61% to C$27K (income), Share-based Payments decrease of 20% to C$9K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $40.80M as of Mar 31, 2020
Annual revenue (TTM): $23.01M as of Mar 31, 2020
EBITDA (TTM): $7.45M as of Mar 31, 2020
Net annual income (TTM): $4.84M as of Mar 31, 2020
Free cash flow (TTM): $5.14M as of Mar 31, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 12,989,570 as of May 27, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization